Document:

tcon_Ex_1015

		

			 

		

		
			Exhibit 10.15
		

		
			FOURTH AMENDMENT TO LEASE
		

		
			This FOURTH AMENDMENT TO LEASE (this "Fourth Amendment") is made and entered into as of the 30 day of November,  2015, by and between RP AVENTINE OFFICE OWNER, L.L.C., a Delaware limited liability company ("Landlord"), and TRACON PHARMACEUTICALS, INC., a Delaware corporation ("Tenant").
		

		
			r e c i t a l s  :
		

		
			A.    Landlord, as successor-in-interest to Glenborough Aventine, LLC, and Tenant, entered into that certain Office Lease dated February 10, 2011 (the "Office Lease"), as amended by that certain First Amendment dated September 16, 2013 (the "First Amendment"), that certain Second Amendment dated September 15, 2014 (the "Second Amendment"), and that certain Third Amendment dated February 20, 2015 (the "Third Amendment") (the Office Lease, the First Amendment, the Second Amendment, and the Third Amendment shall hereafter collectively be referred to as the "Lease"), whereby Landlord leases to Tenant and Tenant leases from Landlord that certain space commonly known as Suites 700, 725, and 780 (the "Existing Premises") and located on the seventh (7th) floor of the building located at 8910 University Center Lane, San Diego, California 92122 (the "Building").
		

		
			B.    Landlord and Tenant desire to expand the Existing Premises to include that certain space consisting of approximately 1,917 rentable (1,611 usable) square feet of space commonly known as a portion of Suite 750 and located on the seventh (7th) floor of the Building (the "Expansion Premises"), as delineated on Exhibit A attached hereto and made a part hereof, and (iii) to make other modifications to the Lease, and in connection therewith, Landlord and Tenant desire to amend the Lease as hereinafter provided.
		

		
			a g r e e m e n t  :
		

		
			NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
		

		
			1.    Capitalized Terms.  All capitalized terms when used herein shall have the same meaning as is given such terms in the Lease unless expressly superseded by the terms of this Fourth Amendment.
		

		
			2.     Modification of Premises.  Effective as of the date (the "Expansion Commencement Date") which is the earlier to occur of (i) the date upon which Tenant first commences to conduct business in the Expansion Premises, and (ii) January 1, 2016 (the "Tenant Work Letter"),  Tenant shall lease from Landlord and Landlord shall lease to Tenant the Expansion Premises.  Consequently, effective upon the Expansion Commencement Date, the Existing Premises shall be increased to include the Expansion Premises.  Landlord and Tenant hereby acknowledge that such addition of the Expansion Premises to the Existing Premises shall, effective as of the Expansion Commencement Date, increase the size of the Existing Premises to 
		

		 

			

					

						742075.04/WLA

					

						375056-00001/2-18-16/bkc/bkc

					

					

						 

					

					

						 

					

						THE AVENTINE

					

						[Fourth Amendment]

					

						[Tracon Pharmaceuticals, Inc.]

				

		

			 

		

 

		
			approximately 9,339 rentable square feet.  The Existing Premises and the Expansion Premises may hereinafter collectively be referred to as the "Premises."    
		

		
			3.     Term of Lease.  The term of Tenant’s lease of the Expansion Premises shall commence on the Expansion Commencement Date and shall expire coterminously with Tenant's lease of the Existing Premises on April 30, 2017 (the "Expansion Expiration Date").  The period of time commencing on the Expansion Commencement Date and expiring on the Expansion Expiration Date shall be referred to herein as the "Expansion Term."    For purposes of this Fourth Amendment, the term "Lease Month" shall mean each succeeding calendar month during the Expansion Term; provided that the first Lease Month shall commence on the Expansion Commencement Date and shall end on the last day of the first full calendar month of the Expansion Term and that the last Lease Month shall expire on the Expansion Expiration Date.  
		

		
			4.     Base Rent.  Commencing on the Expansion Commencement Date and continuing throughout the Expansion Term, Tenant shall pay to Landlord monthly installments of Base Rent for the Expansion Premises as follows:
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						Approximate

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						Monthly

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						Monthly

					
					
						 

					
					
						Rental Rate

					
					
						 

				
	
					
						Period During

					
					
						 

					
					
						Annualized

					
					
						 

					
					
						Installment

					
					
						 

					
					
						per Rentable

					
					
						 

				
	
					
						Expansion Term

					
					
						    

					
					
						Base Rent

					
					
						    

					
					
						of Base Rent

					
					
						    

					
					
						Square Foot

					
					
						 

				
	
					
						Expansion Commencement Date – December 31, 2016

					
					
						 

					
97,767.00 
					
					
						 

					
					
						$

					
8,147.25 
					
					
						 

					
					
						$

					
4.25 
					
					
						 

				
	
					
						January 1, 2017 – April 30, 2017

					
					
						 

					
101,217.60 
					
					
						 

					
					
						$

					
8,434.80 
					
					
						 

					
					
						$

					
4.40 
					
					
						 

				

		
			On or before the Expansion Commencement Date, Tenant shall pay to Landlord the Base Rent payable for the Expansion Premises for the first full month of the Expansion Term.
		

		
			5.     Tenant's Proportionate Share of Direct Costs.  Except as specifically set forth in this Section 5, commencing on the Expansion Commencement Date, Tenant shall pay 0.8828% as Tenant's Share of Direct Expenses that are above the Direct Expenses applicable to the 2016 calendar year (the "Base Year") for the Expansion Premises in accordance with the terms of Article 4 of the Office Lease, as amended.
		

		
			6.     Condition.  
		

		
			6.1.     Existing Premises.  Tenant acknowledges that Tenant has been and is in occupancy of the Existing Premises.  Tenant is fully aware of the condition of the Existing Premises, and therefore Tenant shall continue to accept the Existing Premises in its presently existing, "as is" condition and Landlord shall not be obligated to provide or pay for any improvement work or services, except as expressly set forth in the Lease, related to the improvement of the Existing Premises prior to or during the Expansion Term.  Tenant also acknowledges that neither Landlord nor any agent of Landlord has made any representation or
		

		
			
		

		 

			

					

						742075.04/WLA

					

						375056-00001/2-18-16/bkc/bkc

					

					

						-2-

					

					

						 

					

						THE AVENTINE

					

						[Fourth Amendment]

					

						[Tracon Pharmaceuticals, Inc.]

				

		

			 

		

 

		
			warranty regarding the condition of the Existing Premises, the Building or the Project or with respect to the suitability of any of the foregoing for the conduct of Tenant's business.  
		

		
			6.2.     Expansion Premises.  Except as specifically set forth in the Work Letter, Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the Expansion Premises, and Tenant shall accept the Expansion Premises in its presently existing, "as-is" condition.  Notwithstanding the foregoing, Landlord shall construct the improvements in the Expansion Premises, if any, pursuant to the terms of the Tenant Work Letter.    Tenant also acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty regarding the condition of the Expansion Premises, the Building or the Project or with respect to the suitability of any of the foregoing for the conduct of Tenant's business.  
		

		
			7.     Brokers.  Landlord and Tenant hereby warrant to each other that they have had no dealings with any real estate broker or agent in connection with the negotiation of this Fourth Amendment other than Hughes Marino and Jones Lang LaSalle (the "Brokers"), and that they know of no other real estate broker or agent who is entitled to a commission in connection with this Fourth Amendment.  Each party agrees to indemnify and defend the other party against and hold the other party harmless from any and all claims, demands, losses, liabilities, lawsuits, judgments, and costs and expenses (including, without limitation, reasonable attorneys' fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of the indemnifying party's dealings with any real estate broker or agent, other than the Brokers.  The terms of this Section 7 shall survive the expiration or earlier termination of the term of the Lease, as hereby amended.
		

		
			8.     Security Deposit.  Landlord and Tenant acknowledge that, in accordance with Section 8 of the Office Lease, Landlord currently holds the sum of Forty Thousand Four Hundred Forty-One and 99/100 Dollars ($40,441.99) as security for the faithful performance by Tenant of the terms, covenants and conditions of the Lease.  Concurrently with Tenant's execution of this Fourth Amendment, Tenant shall deposit with Landlord an amount equal to Two Thousand Fifty and 46/100 Dollars ($2,050.46) to be held by Landlord as a part of the Security Deposit.  Accordingly, upon such deposit, notwithstanding anything in the Lease to the contrary, the Security Deposit held by Landlord pursuant to the Lease, as hereby amended, shall equal Forty-Two Thousand Four Hundred Ninety-Two and 45/100 Dollars ($42,492.45).
		

		
			9.     Parking.  
		

		
			9.1.     Existing Premises.  Landlord and Tenant hereby acknowledge that, throughout the Expansion Term, with respect to the Existing Premises Tenant shall continue to have the parking rights set forth in the Lease.  
		

		
			9.2.     Expansion Premises.  Tenant shall have the right, but not the obligation, to rent up to six (6) unreserved parking passes (i.e., four  (4) parking passes per each 1,000 usable square feet of the Expansion Premises), all of which unreserved parking spaces shall pertain to the Project parking facility.  Tenant shall rent such unreserved parking passes for the Expansion Premises on a monthly basis throughout the Expansion Term, at Landlord's prevailing rates for the location and type of such parking passes, which rate is currently $75.00 per unreserved parking 
		

		
			
		

		 

			

					

						742075.04/WLA

					

						375056-00001/2-18-16/bkc/bkc

					

					

						-3-

					

					

						 

					

						THE AVENTINE

					

						[Fourth Amendment]

					

						[Tracon Pharmaceuticals, Inc.]

				

		

			 

		

 

		
			pass per month.  Tenant's rights and obligations with respect to such unreserved parking passes shall otherwise be pursuant to the terms of Article 28 of the Office Lease, as amended.  Tenant shall pay a one-time non-refundable charge in the amount of $40.00 (subject to adjustment from time to time by Landlord) per parking pass.  
		

		
			10.     No Further Modification.  Except as set forth in this Fourth Amendment, all of the terms and provisions of the Lease shall apply with respect to the Expansion Premises and shall remain unmodified and in full force and effect.
		

		
			IN WITNESS WHEREOF, this Fourth Amendment has been executed as of the day and year first above written.  
		

		
			 
		

			
					
						"LANDLORD"

					
					
						"TENANT"

				
	
					
						 

					
					
						 

				
	
					
						RP AVENTINE OFFICE OWNER, L.L.C., a 

					
					
						TRACON PHARMACEUTICALS, INC.,

				
	
					
						Delaware limited liability company

					
					
						a Delaware corporation

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Ron J. Hoyl

					
					
						 

					
					
						By:  

					
					
						/s/ Patricia L. Bitar

				
	
					
						 

					
					
						 

				
	
					
						Name: Ron J. Hoyl

					
					
						Name: Patricia L. Bitar

				
	
					
						 

					
					
						 

				
	
					
						Its:  

					
					
						Vice President

					
					
						 

					
					
						Its: 

					
					
						Chief Financial Officer

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						By:  

					
					
						/s/ Charles Theuer

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						Name: Charles Theuer

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						Its: 

					
					
						Chief Executive Officer

				

		
			 
		

		
			 
		

		
			

		 

			

					

						742075.04/WLA

					

						375056-00001/2-18-16/bkc/bkc

					

					

						-4-

					

					

						 

					

						THE AVENTINE

					

						[Fourth Amendment]

					

						[Tracon Pharmaceuticals, Inc.]

				

		

			 

		

 

		

			 

		

EXHIBIT A
		

		
			OUTLINE OF EXPANSION PREMISES
		

		
			VH
		

		
			 
		

		
			

		 

			

					

						742075.04/WLA

					

						375056-00001/2-18-16/bkc/bkc

					

					

						EXHIBIT A

					

						-1-

					

					

						 

					

						THE AVENTINE

					

						[Fourth Amendment]

					

						[Tracon Pharmaceuticals, Inc.]

				

		

			 

		

 

		

			 

		

EXHIBIT B
		

		
			TENANT WORK LETTER
		

		
			This Tenant Work Letter shall set forth the terms and conditions relating to the construction of the tenant improvements in the Expansion Premises which shall be referred to herein as the "Premises".  This Tenant Work Letter is essentially organized chronologically and addresses the issues of the construction of the Premises, in sequence, as such issues will arise during the actual construction of the Premises.  All references in this Tenant Work Letter to Sections of "this Amendment" shall mean the relevant portion of the Fourth Amendment to which this Tenant Work Letter is attached as Exhibit B and of which this Tenant Work Letter forms a part, all references in this Tenant Work Letter to Articles or Sections of "this Lease" shall mean the relevant portions of the Lease (as amended) being amended by this Amendment, and all references in this Tenant Work Letter to Sections of "this Tenant Work Letter" shall mean the relevant portions of Sections 1 through 6 of this Tenant Work Letter.  All references in this Tenant Work Letter to the "Premises" shall mean the "Expansion Premises."
		

		
			SECTION 1

DELIVERY OF PREMISES; TENANT IMPROVEMENTS
		

		
			1.1     Delivery of Premises.  Landlord shall delivery possession of the Premises to Tenant on or before December 1, 2015.  Tenant hereby acknowledges that the Premises are currently occupied by another tenant of the Building.  If Landlord is unable for any reason to deliver possession of the Premises to Tenant on any specific date, then Landlord shall not be subject to any liability for its failure to do so, and such failure shall not affect the validity of this Lease or the obligations of Tenant hereunder; provided, however, the date set forth in Section 2(ii) of this Fourth Amendment shall be delayed until the date that is thirty (30) days after the date Landlord delivers possession of the Premises to Tenant.  If Landlord does not deliver possession of the Premises to Tenant by March 1, 2016 (the "Outside Date"), then the sole remedy of Tenant for such failure shall be the right to deliver a notice to Landlord (a "Termination Notice") electing to terminate the Lease with respect to the Expansion Premises only effective upon the date occurring five (5) business days following receipt by Landlord of the Termination Notice (the "Effective Date").  The Termination Notice must be delivered by Tenant to Landlord, if at all, not earlier than the Outside Date nor later than five (5) business days after the Outside Date.  The effectiveness of any such Termination Notice delivered by Tenant to Landlord shall be governed by the terms of this Section 1.1.  If Tenant delivers a Termination Notice to Landlord, then Landlord shall have the right to suspend the occurrence of the Effective Date for a period ending thirty (30) days after the Effective Date by delivering written notice to Tenant, prior to the Effective Date, that, in Landlord's reasonable, good faith judgment, Landlord will deliver the Premises to Tenant within thirty (30) days after the Effective Date (the "Termination Extension Notice").  If Landlord delivers the Premises to Tenant within such thirty (30) day suspension period, then the Termination Notice shall be of no force or effect, but if Landlord does not deliver the Premises to Tenant within such thirty (30) day suspension period, then the Lease with respect to the Expansion Premises shall terminate upon the expiration of such thirty (30) day suspension period.  Upon any termination as set forth in this Section 1.1, Landlord and Tenant shall be relieved 
		

		
			
		

		
			

		 

			

					

						742075.04/WLA

					

						375056-00001/2-18-16/bkc/bkc

					

					

						EXHIBIT B

					

						-1-

					

					

						 

					

						THE AVENTINE

					

						[Fourth Amendment]

					

						[Tracon Pharmaceuticals, Inc.]

				

		

			 

		

 

		

			 

		

from any and all liability to each other resulting hereunder with respect to the Expansion Premises, except that Landlord shall return to Tenant any prepaid rent with respect to the Expansion Premises and Landlord shall return the additional Security Deposit amount paid by Tenant pursuant to Section 8 of the Fourth Amendment.  
		

		
			1.2     Tenant Improvements.  If Tenant desires to construct any improvements in the Premises (the "Tenant Improvements"), then Tenant shall have the right to deliver a space plan (a "Space Plan") to Landlord depicted such Tenant Improvements, which Space Plan shall be subject to Landlord's approval, which shall not be unreasonably withheld.  Following Landlord's approval of the Space Plan, Tenant shall cooperate in good faith with Landlord’s architects and engineers to supply such information necessary to allow Landlord’s architects and engineers to prepare architectural and engineering drawings for the Premises in a form which is complete to allow subcontractors to bid on the work and to obtain all applicable permits and in a manner consistent with, and which are a logical extension of, the Space Plan (collectively, the “Original Working Drawings”), and Landlord shall submit the Original Working Drawings to Tenant for its approval, which shall not be unreasonably withheld.  Following Tenant's approval of the Original Working Drawings, Landlord shall provide Tenant with a cost proposal (the "Cost Pricing Proposal") in accordance with the Original Working Drawings for the Premises, which cost proposal shall include, as nearly as possible, the cost to be incurred in connection with the performance of the Tenant Improvements.  Within five (5) business days, Tenant shall either (i) approve the Cost Pricing Proposal or (ii) disapprove the Cost Pricing Proposal and provide Landlord with Tenant's proposed revisions to the same, which proposed revisions shall be subject to Landlord's approval, not to be unreasonably withheld, conditioned or delayed.  Upon Landlord's receipt of Tenant's approval of the Cost Pricing Proposal or upon Tenant's failure to timely delivery notice of its approval of the same, Landlord shall construct the Tenant Improvements pursuant to the Original Working Drawings.   In the event that Tenant disapproves of the Cost Pricing Proposal, Landlord shall cause its architects and engineers to modify the Original Working Drawings in a manner consistent with, and which are a logical extension of Tenant's proposed revisions.  Thereafter, Landlord shall construct the Tenant Improvements pursuant to such modified Original Working Drawings (the "Modified Working Drawings").  As used in this Tenant Work Letter, the term "Approved Working Drawings" shall mean either the Original Working Drawings or the Modified Working Drawings, as applicable.  Except as set forth above, Tenant shall make no changes or modifications to the Approved Working Drawings, without the prior written consent of Landlord.    Landlord shall cause the Premises to comply with applicable laws, at Landlord's sole cost and expense, to the extent required in order to allow Tenant to obtain a certificate of occupancy, or its legal equivalent, for the Premises for general office use assuming a normal and customary office occupancy density.
		

		
			1.3     No Constructive Eviction.  If all or any portion of the Tenant Improvements shall be constructed by Landlord on or after the Expansion Commencement Date, then (i) Landlord shall be permitted to complete the Tenant Improvements during normal business hours, (ii) Tenant shall provide a clear working area for the construction of the Tenant Improvements, and (iii) Tenant shall cooperate with all reasonable Landlord requests made in connection with Landlord's completion of the Tenant Improvements.  Tenant hereby acknowledges that the construction the Tenant Improvements during Tenant's occupancy of the Premises shall in no way constitute a
		

		
			
		

		
			

		 

			

					

						742075.04/WLA

					

						375056-00001/2-18-16/bkc/bkc

					

					

						EXHIBIT B

					

						-2-

					

					

						 

					

						THE AVENTINE

					

						[Fourth Amendment]

					

						[Tracon Pharmaceuticals, Inc.]

				

		

			 

		

 

		

			 

		

constructive eviction of Tenant nor entitle Tenant to any abatement of rent or damages of any kind (including damages relating to any interference with Tenant's business at the Premises).
		

		
			 
		

		
			SECTION 2

OVER-ALLOWANCE AMOUNT
		

		
			Landlord has allocated an amount (the “Tenant Improvement Allowance”) not to exceed Nine Thousand Five Hundred Eighty-Five and 00/100 Dollars ($9,585.00) (i.e., $5.00 for each of the rentable square feet of the Expansion Premises) for the costs of designing and constructing the Tenant Improvements.  In the event that Landlord reasonably anticipates that the total cost of designing and constructing the Tenant Improvements will exceed the Tenant Improvement Allowance, the amount of such reasonably anticipated excess shall be paid by Tenant to Landlord immediately upon Landlord’s request as an over-allowance amount (the "Over-Allowance Amount").  The Over-Allowance Amount shall be disbursed by Landlord prior to the disbursement of any remaining portion of Landlord's contribution to the construction of the Tenant Improvements.  In the event that after Tenant's approval of the Approved Working Drawings, any revisions, changes, or substitutions shall be made to (i) the Approved Working Drawings (once the same are completed), or (ii) the Tenant Improvements, then any additional costs which arise in connection with such revisions, changes or substitutions shall be paid by Tenant to Landlord immediately upon Landlord's request as an addition to the Over-Allowance Amount.    In the event that the Tenant Improvement Allowance is not fully disbursed by Landlord to, or on behalf of, Tenant on or before July 1, 2016, then such unused amounts shall revert to Landlord, and Tenant shall have no further rights with respect thereto; provided, however, Tenant may, pursuant to written notice delivered to Landlord on or before December 31, 2015, elect to apply all or a portion of the Tenant Improvement Allowance as an offset against Base Rent next due and owing by Tenant under the terms of the Lease, as amended hereby.  
		

		
			SECTION 3

CONTRACTOR'S WARRANTIES AND GUARANTIES
		

		
			Landlord hereby assigns to Tenant all warranties and guaranties by the contractor who constructs the Tenant Improvements (the "Contractor") relating to the Tenant Improvements, and Tenant hereby waives all claims against Landlord relating to, or arising out of the construction of, the Tenant Improvements;  provided, however, that if, within 30 days after Substantial Completion of the Tenant Improvement Work, Tenant provides notice to Landlord of any non-latent defect in the Tenant Improvements, or if, within eleven (11) months after Substantial Completion of the Tenant Improvement Work, Tenant provides notice to Landlord of any latent defect in the Tenant Improvements, then Landlord shall promptly cause such defect to be corrected.
		

		
			

		 

			

					

						742075.04/WLA

					

						375056-00001/2-18-16/bkc/bkc

					

					

						EXHIBIT B

					

						-3-

					

					

						 

					

						THE AVENTINE

					

						[Fourth Amendment]

					

						[Tracon Pharmaceuticals, Inc.]

				

		

			 

		

 

		

			 

		

 
		

		
			SECTION 4

INTENTIONALLY OMITTED
		

		
			SECTION 5

MISCELLANEOUS
		

		
			5.1     Tenant's Entry Into the Premises Prior to Substantial Completion.  Provided that Tenant and its agents do not interfere with Contractor's work in the Building and the Premises, Contractor shall allow Tenant access to the Premises prior to the Substantial Completion of the Premises for the purpose of Tenant installing overstandard equipment or fixtures (including Tenant's data and telephone equipment) in the Premises.  Prior to Tenant's entry into the Premises as permitted by the terms of this Section 5.1, Tenant shall submit a schedule to Landlord and Contractor, for their approval, which schedule shall detail the timing and purpose of Tenant's entry.  Tenant shall hold Landlord harmless from and indemnify, protect and defend Landlord against any loss or damage to the Building or Premises and against injury to any persons caused by Tenant's actions pursuant to this Section 5.1.
		

		
			5.2     Tenant's Representative.  Tenant has designated Arlene Bolz as its sole representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Landlord, shall have full authority and responsibility to act on behalf of the Tenant as required in this Tenant Work Letter.
		

		
			5.3     Landlord's Representative.  Landlord has designated Michael Coleman as its sole representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of the Landlord as required in this Tenant Work Letter.
		

		
			5.4     Time of the Essence in This Tenant Work Letter.  Unless otherwise indicated, all references herein to a "number of days" shall mean and refer to calendar days.  In all instances where Tenant is required to approve or deliver an item, if no written notice of approval is given or the item is not delivered within the stated time period, at Landlord's sole option, at the end of such period the item shall automatically be deemed approved or delivered by Tenant and the next succeeding time period shall commence.
		

		
			5.5     Tenant's Lease Default.  Notwithstanding any provision to the contrary contained in this Fourth Amendment, if an event of default as described in the Lease, as amended, or a default by Tenant under this Tenant Work Letter, has occurred at any time on or before the Substantial Completion of the Expansion Premises, following any applicable notice and cure periods, then (i) in addition to all other rights and remedies granted to Landlord pursuant to the Lease, as amended, Landlord shall have the right to cause Contractor to cease the construction of the Expansion Premises (in which case, Tenant shall be responsible for any delay in the Substantial Completion of the Expansion Premises caused by such work stoppage as set forth in Section 4 of this Tenant Work Letter), and (ii) all other obligations of Landlord under the terms of this Tenant Work Letter shall be forgiven until such time as such default is cured pursuant to the terms of the Lease.
		

		 

			

					

						742075.04/WLA

					

						375056-00001/2-18-16/bkc/bkc

					

					

						EXHIBIT B

					

						-4-

					

					

						 

					

						THE AVENTINE

					

						[Fourth Amendment]

					

						[Tracon Pharmaceuticals, Inc.]tcon_Ex_1017

		

			Exhibit 10.17

		

		

			 

		

		

			***Text Omitted and Filed Separately with

		

		

			the Securities and Exchange Commission.

		

		

			Confidential Treatment Requested Under 

		

		

			17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

		

		

			 

		

		
			 
		

		
			SECOND AMENDMENT TO LICENSE AGREEMENT
		

		
			 
		

		
			This SECOND AMENDMENT TO LICENSE AGREEMENT (“2nd Amendment”) is entered into as of January 31, 2016 (the “2nd Amendment Effective Date”) by and between Santen Pharmaceutical Co., Ltd., a company organized under the laws of Japan (“Santen”) and TRACON Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (“Tracon”).
		

		
			 
		

		
			RECITALS
		

		
			 
		

		
			A.Santen and Tracon are parties to that certain License Agreement, dated March 3, 2014 and as amended December 31, 2014 (the “Agreement”).
		

		
			 
		

		
			B.Santen Inc. (Santen’s Affiliate in the United States) and Tracon have entered into CONTRACT RESEARCH ORGNIZATION (CRO) MASTER SERVICE AGREEMENT, dated August 15, 2015 (the “CRO MSA”), and Tracon performs services for Santen Inc. under the CRO MSA (the “Service by CRO MSA”).
		

		
			 
		

		
			C.The Parties have agreed to amend the Agreement as set forth herein.
		

		
			 
		

		
			NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Tracon and Santen hereby agree as follows:
		

		
			 
		

			
	
			
				 1.
			

			
	
			
			Defined Terms. All capitalized terms not otherwise defined in this 2nd Amendment shall have the same meanings that are described to them in the Agreement.

		
			 
		

			
	
			
				 2.
			

			
	
			
			Deletion of Section 2.6(b).  The Parties agree to delete Section 2.6(b) of the Agreement based on the fact that Tracon has already provided such first [...***...] free of charge to Santen.

		
			 
		

			
	
			
				 3.
			

			
	
			
			Amendment of Section 2.7. Section 2.7 of the Agreement is hereby amended and restated in its entirety as follows:

		
			 
		

		
			“2.7  Consulting Services.    Each Party agrees to provide the Consulting Services (as defined below) to the other Party, as reasonably requested in writing by the other Party, although Tracon may, in certain instances, provide Consulting Services to satisfy regulatory and/or GMP requirements before notification of Santen.  Such Consulting Services may be provided through email correspondence, in-person meetings or video/audio conferences.  In addition, Tracon may use consultants and contractors (including its contract manufacturers) to perform Consulting Services in direct support of Santen and shall notify Santen in advance when consultants and/or contractors are going to be used for such activities, including for example, batch record review, auditing and person in plant,  which will be coordinated by Tracon,  provided however, in no event shall the Consulting Services exceed [...***...]  hours during any calendar quarter in principle except as otherwise agreed between Tracon and Santen.
		

		
			 
		

		
			

		 

		

			***Confidential Treatment Requested

		

		

			 

		

		

			 

		

 

		

			***Text Omitted and Filed Separately with

		

		

			the Securities and Exchange Commission.

		

		

			Confidential Treatment Requested Under 

		

		

			17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

		

		

			 

		

For purposes of this provision, “Consulting Services” shall mean 
		

		
			 
		

		
			(i)   provision of information regarding development and regulatory activities with respect to the Products and Tracon Products except for information exchanged through the JDC, 
		

		
			 
		

		
			(ii)   provision of any safety information with respect to the Products and Tracon Products at the request of a Party other than the information exchanged under a safety data exchange agreement entered into by the Parties pursuant to Section 3.2(c), 
		

		
			 
		

		
			(iii)  provision of regulatory support with respect to the Products and Tracon Products including, without limitation, review of the regulatory documents (IND, BLA etc.), participation in meetings with Regulatory Authorities (including the FDA) and responding to inquiries from any Regulatory Authority, and
		

		
			 
		

		
			(iv)   provision of services related to coordination (including scheduling of activities, shipping activities and negotiation of agreements) with Tracon’s contract manufacturer. For the purpose of provision of this clause (iv), Tracon shall provide Santen access to Tracon employees and consultants, to the extent such consultants are available, and shall use reasonable efforts to enable Santen to have access to employees and consultants of its contractors (including its contract manufacturers), as reasonably necessary to assist in connection with the shipping (including necessary support) of reagent and TRC105 sample supply for non-clinical/CMC purposes upon Santen’s request and prior written consent, provided however that, shall exclude the Service by CRO MSA. 
		

		
			 
		

			
	
			
				 4.
			

			
	
			
			Service under CRO MSA

		
			 
		

		
			Tracon agrees to use its best efforts to perform its service under the CRO MSA. Tracon and Santen acknowledge that if Tracon may not provide the service under the CRO MSA in spite of Tracon’s best efforts, such service should be covered by this amended Section 2.7 of the Agreement.
		

		
			 
		

			
	
			
				 5.
			

			
	
			
			Invoicing and Payment Process. 

		
			 
		

		
			The Parties agree to adopt the following revised invoicing and payment process:
		

		
			 
		

		
			For all Consulting Services provided by Tracon to Santen and for the reimbursement of all activities in Exhibit D-1, Tracon will invoice Santen within ten (10) days following the end of each calendar month, each invoice to contain reasonably detailed timesheets and backup documentation for all Exhibit D-1 activities.  Santen agrees to pay such invoices within thirty (30) days of receipt.  Santen agrees to reimburse Tracon for Consulting Services provided by Tracon employees at a rate of [...***...] per hour, which rate shall be reviewed annually by the Parties.  
		

		
			 
		

		
			For Consulting Services provided by Tracon using consultants and contractors (including its contract manufacturers), Santen agrees to reimburse Tracon at the same rate that Tracon has negotiated with the consultant(s) or contractors, but if the amount is over [...***...] per hour, Tracon will give advance notice to Santen.
		

		
			 
		

		
			For all activities that are solely attributable to Santen (as detailed in Exhibit D-2), Tracon will invoice Santen upon receipt of the third party invoice and will provide a copy of the third party invoice to Santen, 

		 

		

			***Confidential Treatment Requested

		

		

			 

		

 

		

			***Text Omitted and Filed Separately with

		

		

			the Securities and Exchange Commission.

		

		

			Confidential Treatment Requested Under 

		

		

			17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

		

		

			 

		

with payment due no later than 20 days to Tracon to allow Tracon to timely submit payment to the third party vendor within their stated contractual terms.
		

		
			 
		

		
			If Tracon requests that Santen provide Consulting Services, Tracon shall reimburse Santen for such Consulting Services at a rate of U.S. $[...***...] per hour.
		

		
			 
		

			
	
			
				 6.
			

			
	
			
			Quarterly Update of Exhibit D-1. Tracon and Santen shall revise and update Exhibit D-1 to have the schedule for next 18 months on a quarterly basis.  Any disagreements between the Parties on the inclusion of sharing of those costs in Exhibit D-1 shall be brought to the JDC for resolution.

		
			 
		

			
	
			
				 7.
			

			
	
			
			Newly created Exhibit D-2 and Quarterly Update of Exhibit D-2.  Tracon and Santen shall create and update Exhibit D-2 (those activities that are in direct support of Santen but are coordinated by Tracon and to be reimbursed 100% by Santen) to have the schedule for next 18 months on a quarterly basis. Upon request by Santen, Tracon agrees to request the necessary cost information for the activities (i.e. cost of goods, manufacturing plan of drug substance) from the third party service providers or contract manufacturer. 

		
			 
		

			
	
			
				 8.
			

			
	
			
			Amendment of Section 3.4. Section 3.4 of the Agreement is hereby amended and restated in its entirety as follows:

		
			 
		

		
			“3.4  Manufacture and Supply.  During the Term, Tracon shall, or shall cause [...***...] to supply the Compound to Santen as ordered by Santen from time to time, subject to the terms of this Section 3.4.  Santen agrees to purchase Compounds from [...***...] for use in manufacturing Products for the [...***...], pursuant to a written supply agreement, which shall be separately discussed and agreed in good faith by the Parties (the “Supply Agreement”), and will include the terms set forth on Exhibit D, which purchase and supply of Compounds may be accomplished through the Consulting Services or through the purchase order process used by the Parties.  Santen may purchase Compounds manufactured by [...***...] for  use in manufacturing Products for [...***...], pursuant to a written supply agreement, which shall be separately discussed and agreed in good faith by Santen with Tracon or [...***...].”
		

		
			 
		

			
	
			
				 9.
			

			
	
			
			Continuing Effect.  All references to the “Agreement” in the Agreement shall hereinafter refer to the Agreement as amended by this 2nd Amendment.  Except as specifically amended by this 2nd Amendment, the Agreement shall remain in full force and effect in accordance with its terms.  Sections or other headings contained in this 2nd Amendment are for reference purposes only and shall not affect in any way the meaning or interpretation of this 2nd Amendment; and no provision of this 2nd Amendment shall be interpreted for or against any Party because that Party or its legal representative drafted the provision.

		
			 
		

			
	
			
				 10.
			

			
	
			
			Counterparts.  This 2nd Amendment may be executed in counterparts with the same force and effect as if each of the signatories had executed the same instrument.

		
			 
		

		
			 
		

		
			[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]
		

		
			 
		

		
			 
		

		
			

		 

		

			***Confidential Treatment Requested

		

		

			 

		

 

		

			***Text Omitted and Filed Separately with

		

		

			the Securities and Exchange Commission.

		

		

			Confidential Treatment Requested Under 

		

		

			17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

		

		

			 

		

IN WITNESS WHEREOF, the Parties have executed this 2nd Amendment as of the 2nd Amendment Effective Date.
		

		
			 
		

		
			 
		

			
					
						TRACON PHARMACEUTICALS, INC.

					
					
						    

					
					
						SANTEN PHARMACEUTICAL CO., LTD.    

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Charles P. Theuer, M.D., Ph.D.

					
					
						 

					
					
						By:

					
					
						/s/ Naveed Shams

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Name:

					
					
						Charles Theuer, M.D., Ph.D.

					
					
						 

					
					
						Name:

					
					
						Naveed Shams

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Title:

					
					
						President and CEO

					
					
						 

					
					
						Title:

					
					
						Chief Scientific Officer, 

				
	
					
						 

					
					
						Head of R&D Division

				

		
			 
		

		 

		

			SIGNATURE PAGE TO SECOND AMENDMENT TO LICENSE AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]